Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 29;4(1):vdac158. doi: 10.1093/noajnl/vdac158

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Clinico-molecular markers and outcome in IDH-wildtype glioblastoma with or without TERT promotor mutations. (A) Distribution of MGMT promotor methylation status (upper panel) and first-line therapies following surgery (lower panel) in IDH-wildtype glioblastomas with (IDH^wt/TERT^mut; n = 396) or without TERT promotor mutations (IDH^wt/TERT^wt; n = 70). (B) Pre- (upper panel) and postoperative tumor volumes (lower panel) in cm³ among IDH-wildtype glioblastomas undergoing microsurgical tumor resection with (IDH^wt/TERT^mut; n = 358; green) or without TERT promotor mutations (IDH^wt/TERT^wt; n = 63; blue). Volumes are indicated for contrast-enhancing (CE) and noncontrast-enhancing (nCE) tumor tissue. Median ± interquartile range. (C) Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) for IDH-wildtype glioblastomas with (green line) or without TERT promotor mutations (blue line). Points indicate deceased or censored patients; light shadings indicate SEM.